F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)

F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML

NCT01592266•Hadassah Medical Organization

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Acute Myeloid Leucemia

Locations

Israel

Locations (1)

Hadassah Hebrew University Medical Center

Jerusalem, Israel

Key Dates

Start Date

October 1, 2012

Primary Completion Date

October 1, 2013

Last Updated

May 7, 2012

Contacts

Marina Orevi, MD

CONTACT

marinaor@hadassah.org.il

Sponsors

Lead Sponsor

Hadassah Medical Organization

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions